Drug Profile


Alternative Names: 5F 203 prodrug; NSC-710305

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research UK
  • Developer Pharminox
  • Class Antineoplastics; Small molecules; Thiazoles
  • Mechanism of Action Apoptosis stimulants; Cytochrome P-450 enzyme system stimulants; DNA cross linking agents; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in United Kingdom (IV-injection, Injection)
  • 20 Dec 2006 Phortress is still in phase I trials for Cancer in United Kingdom
  • 04 May 2004 Phase-I clinical trials in Cancer in United Kingdom (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top